189 related articles for article (PubMed ID: 11919668)
1. Ondansetron reduces the craving of biologically predisposed alcoholics.
Johnson BA; Roache JD; Ait-Daoud N; Zanca NA; Velazquez M
Psychopharmacology (Berl); 2002 Apr; 160(4):408-13. PubMed ID: 11919668
[TBL] [Abstract][Full Text] [Related]
2. Ondansetron reduces mood disturbance among biologically predisposed, alcohol-dependent individuals.
Johnson BA; Ait-Daoud N; Ma JZ; Wang Y
Alcohol Clin Exp Res; 2003 Nov; 27(11):1773-9. PubMed ID: 14634493
[TBL] [Abstract][Full Text] [Related]
3. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence.
Johnson BA; Ait-Daoud N; Prihoda TJ
Alcohol Clin Exp Res; 2000 May; 24(5):737-42. PubMed ID: 10832917
[TBL] [Abstract][Full Text] [Related]
4. Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: preliminary clinical evidence.
Ait-Daoud N; Johnson BA; Prihoda TJ; Hargita ID
Psychopharmacology (Berl); 2001 Feb; 154(1):23-7. PubMed ID: 11292002
[TBL] [Abstract][Full Text] [Related]
5. Reductions in and relations between "craving" and drinking in a prospective, open-label trial of ondansetron in adolescents with alcohol dependence.
Dawes MA; Johnson BA; Ma JZ; Ait-Daoud N; Thomas SE; Cornelius JR
Addict Behav; 2005 Oct; 30(9):1630-7. PubMed ID: 16084024
[TBL] [Abstract][Full Text] [Related]
6. Combining ondansetron and naltrexone treats biological alcoholics: corroboration of self-reported drinking by serum carbohydrate deficient transferrin, a biomarker.
Ait-Daoud N; Johnson BA; Javors M; Roache JD; Zanca NA
Alcohol Clin Exp Res; 2001 Jun; 25(6):847-9. PubMed ID: 11410720
[TBL] [Abstract][Full Text] [Related]
7. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial.
Johnson BA; Roache JD; Javors MA; DiClemente CC; Cloninger CR; Prihoda TJ; Bordnick PS; Ait-Daoud N; Hensler J
JAMA; 2000 Aug 23-30; 284(8):963-71. PubMed ID: 10944641
[TBL] [Abstract][Full Text] [Related]
8. Effects of ondansetron in early- versus late-onset alcoholics: a prospective, open-label study.
Kranzler HR; Pierucci-Lagha A; Feinn R; Hernandez-Avila C
Alcohol Clin Exp Res; 2003 Jul; 27(7):1150-5. PubMed ID: 12878921
[TBL] [Abstract][Full Text] [Related]
9. Prediction of serotonergic treatment efficacy using age of onset and Type A/B typologies of alcoholism.
Roache JD; Wang Y; Ait-Daoud N; Johnson BA
Alcohol Clin Exp Res; 2008 Aug; 32(8):1502-12. PubMed ID: 18565156
[TBL] [Abstract][Full Text] [Related]
10. Ondansetron alters human alcohol intoxication.
Swift RM; Davidson D; Whelihan W; Kuznetsov O
Biol Psychiatry; 1996 Sep; 40(6):514-21. PubMed ID: 8879472
[TBL] [Abstract][Full Text] [Related]
11. A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence.
Balldin J; Berglund M; Borg S; Månsson M; Bendtsen P; Franck J; Gustafsson L; Halldin J; Nilsson LH; Stolt G; Willander A
Alcohol Clin Exp Res; 2003 Jul; 27(7):1142-9. PubMed ID: 12878920
[TBL] [Abstract][Full Text] [Related]
12. A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue.
Theal JJ; Toosi MN; Girlan L; Heslegrave RJ; Huet PM; Burak KW; Swain M; Tomlinson GA; Heathcote EJ
Hepatology; 2005 Jun; 41(6):1305-12. PubMed ID: 15915460
[TBL] [Abstract][Full Text] [Related]
13. A pilot double-blind treatment trial of memantine for alcohol dependence.
Evans SM; Levin FR; Brooks DJ; Garawi F
Alcohol Clin Exp Res; 2007 May; 31(5):775-82. PubMed ID: 17378918
[TBL] [Abstract][Full Text] [Related]
14. Psychometric properties of the Penn Alcohol Craving Scale.
Flannery BA; Volpicelli JR; Pettinati HM
Alcohol Clin Exp Res; 1999 Aug; 23(8):1289-95. PubMed ID: 10470970
[TBL] [Abstract][Full Text] [Related]
15. A prospective, open-label trial of ondansetron in adolescents with alcohol dependence.
Dawes MA; Johnson BA; Ait-Daoud N; Ma JZ; Cornelius JR
Addict Behav; 2005 Jul; 30(6):1077-85. PubMed ID: 15925118
[TBL] [Abstract][Full Text] [Related]
16. A double-blind placebo-controlled pilot study of risperidone for decreasing cue-elicited craving in recently withdrawn cocaine dependent patients.
Smelson DA; Williams J; Ziedonis D; Sussner BD; Losonczy MF; Engelhart C; Kaune M
J Subst Abuse Treat; 2004 Jul; 27(1):45-9. PubMed ID: 15223093
[TBL] [Abstract][Full Text] [Related]
17. Naltrexone's effect on cue-elicited craving among alcoholics in treatment.
Monti PM; Rohsenow DJ; Hutchison KE; Swift RM; Mueller TI; Colby SM; Brown RA; Gulliver SB; Gordon A; Abrams DB
Alcohol Clin Exp Res; 1999 Aug; 23(8):1386-94. PubMed ID: 10470982
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of and physiological responses to nitrous oxide gas treatment during alcohol withdrawal: a double-blind, placebo-controlled trial.
Alho H; Methuen T; Paloheimo M; Strid N; Seppä K; Tiainen J; Salaspuro M; Roine R
Alcohol Clin Exp Res; 2002 Dec; 26(12):1816-22. PubMed ID: 12500105
[TBL] [Abstract][Full Text] [Related]
19. Citalopram neuropharmacological challenge in alcohol-dependent patients and controls: pharmacogenetic, endocrine and psychobehavioral results.
Wong WM; Hasemann S; Schwarz M; Zill P; Koller G; Soyka M; Preuss UW
Pharmacopsychiatry; 2008 Mar; 41(2):72-8. PubMed ID: 18311688
[TBL] [Abstract][Full Text] [Related]
20. Effect of nicotine lozenges on affective smoking withdrawal symptoms: secondary analysis of a randomized, double-blind, placebo-controlled clinical trial.
Shiffman S
Clin Ther; 2008 Aug; 30(8):1461-75. PubMed ID: 18803988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
